Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation

Alois Gratwohl1, Ronald Brand, Dietger Niederwieser

  • 1European Group for Blood and Marrow Transplantation Activity Survey Office, University Hospital, Basel, Switzerland. hematology@uhbs.ch

Insights

The Joint Accreditation Committee International Society for Cellular Therapy and the European Group for Blood and Marrow Transplantation (JACIE) accreditation improved patient survival in hematopoietic stem-cell transplantation (HSCT). This quality management system enhanced outcomes for both allogeneic and autologous HSCT procedures.

Area of Science:

  • Hematology
  • Transplantation Medicine
  • Quality Management

Background:

  • Hematopoietic stem-cell transplantation (HSCT) is a critical treatment for hematologic disorders.
  • Ensuring high-quality care in HSCT is essential for patient outcomes.
  • The Joint Accreditation Committee International Society for Cellular Therapy and the European Group for Blood and Marrow Transplantation (JACIE) was established to standardize and improve HSCT quality.

Purpose of the Study:

  • To evaluate the impact of JACIE accreditation on patient survival after HSCT.
  • To test the hypothesis that implementing a comprehensive quality management system improves HSCT outcomes.

Main Methods:

  • Analysis of data from 41,623 allogeneic and 66,281 autologous HSCTs performed between 1999-2007 across 421 European teams.
  • Outcomes were assessed at different stages relative to JACIE accreditation: baseline, preparation, application, and post-accreditation.
  • Statistical analysis was clustered by team and stratified by year, donor type, disease, conditioning, and country's gross national income, adjusting for European Group for Blood and Marrow Transplantation scores.

Main Results:

  • Patient outcomes significantly improved with more advanced stages of JACIE accreditation.
  • Relapse-free survival showed improvement after JACIE accreditation for allogeneic HSCT (HR 0.86, P=.01) and autologous HSCT (HR 0.83, P<.01) compared to baseline.
  • These improvements were consistent across various risk factors and transplantation years.

Conclusions:

  • The introduction of a comprehensive clinical quality management system like JACIE is associated with improved patient outcomes in HSCT.
  • Findings support the hypothesis that standardized quality management positively impacts HSCT success rates.
  • Observational data suggest JACIE accreditation contributes to better patient survival and reduced relapse rates.
Abstract

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...